Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coseasonal initiation of Artemisia annua SLIT for allergic rhinoconjunctivitis
ChiCTR2400085511Phase 4Not yet recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of artemisia annua in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Ordos Central Hospital. Primary endpoint: Combined symptom and medication score for rhinoconjunctivitis. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
artemisia annua
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on ChiCTR2400085511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085511.